Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours

NICE technology appraisals [TA265] Published date:

Adults with cancer that has spread to the bone from solid tumours except for prostate cancer

NICE recommends denosumab as a possible treatment for preventing complications that result from cancer spreading to the bone from solid tumours, except for prostate cancer, if the person would otherwise be prescribed a type of drug called a bisphosphonate.

Adults with cancer that has spread to the bone from prostate cancer

NICE does not recommend denosumab for preventing complications that result from prostate cancer spreading to the bone.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS.

In people with breast cancer that has spread to the bone NICE recommended denosumab because it works better and, because it works better, is likely to cost the NHS less overall than other treatments available on the NHS.

In people with cancer that has spread to the bone from solid tumours, except breast and prostate cancer, NICE recommended denosumab because it works better than bisphosphonates. Although it also costs more than other treatments, this was justified by the benefits it provided.

In people with prostate cancer that has spread to the bone denosumab does not provide enough benefit to patients to justify its high cost so NICE did not recommend it.

Get involved